Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The interferon—cancer trials: hardly hopeless but not too heartening

The interferon—cancer trials: hardly hopeless but not too heartening The honeymoon is over. After years of intensive study, cancer researchers are no longer making glowing predictions about interferon's anticancer effects. Instead, new data from a number of phase II clinical trials indicate that large doses of pure interferon produced by genetic engineering techniques have only limited effects against some tumor types and no effect against others. Such studies have also confirmed that the most commonly tested subtype of interferon is inherently toxic, causing side effects in patients that range from mild to life-threatening. A number of reports were presented at the recent tandem meetings of the American Society of Clinical Oncology and the American Association for Cancer Research in San Diego. Several concerned two leukocyte interferons [IFN-α] produced with recombinant DNA technology. One is rIFN-αA, distributed by Hoffmann-LaRoche, Inc, Nutley, NJ, and the other is rIFN-α2, from Schering-Plough Corporation, Kenilworth, NJ. The two molecules are essentially the same—differing only http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

The interferon—cancer trials: hardly hopeless but not too heartening

JAMA , Volume 250 (8) – Aug 26, 1983

Loading next page...
 
/lp/american-medical-association/the-interferon-cancer-trials-hardly-hopeless-but-not-too-heartening-EZPNXo8uO0

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright © 1983 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1983.03340080003001
Publisher site
See Article on Publisher Site

Abstract

The honeymoon is over. After years of intensive study, cancer researchers are no longer making glowing predictions about interferon's anticancer effects. Instead, new data from a number of phase II clinical trials indicate that large doses of pure interferon produced by genetic engineering techniques have only limited effects against some tumor types and no effect against others. Such studies have also confirmed that the most commonly tested subtype of interferon is inherently toxic, causing side effects in patients that range from mild to life-threatening. A number of reports were presented at the recent tandem meetings of the American Society of Clinical Oncology and the American Association for Cancer Research in San Diego. Several concerned two leukocyte interferons [IFN-α] produced with recombinant DNA technology. One is rIFN-αA, distributed by Hoffmann-LaRoche, Inc, Nutley, NJ, and the other is rIFN-α2, from Schering-Plough Corporation, Kenilworth, NJ. The two molecules are essentially the same—differing only

Journal

JAMAAmerican Medical Association

Published: Aug 26, 1983

There are no references for this article.